Literature DB >> 8890165

The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.

T Davis-Smyth1, H Chen, J Park, L G Presta, N Ferrara.   

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic inducer that mediates its effects through two high affinity receptor tyrosine kinases, Flt-1 and KDR. Flt-1 is required for endothelial cell morphogenesis whereas KDR is involved primarily in mitogenesis. Flt-1 has an alternative ligand, placenta growth factor (PlGF). Both Flt-1 and KDR have seven immunoglobulin (Ig)-like domains in the extracellular domain. The significance and function of these domains for ligand binding and receptor activation are unknown. Here we show that deletion of the second domain of Flt-1 completely abolishes the binding of VEGF. Introduction of the second domain of KDR into an Flt-1 mutant lacking the homologous domain restored VEGF binding. However, the ligand specificity was characteristic of the KDR receptor. We then created chimeric receptors where the first three or just the second Ig-like domains of Flt-1 replaced the corresponding domains in Flt-4, a receptor that does not bind VEGF, and analyzed their ability to bind VEGF. Both swaps conferred upon Flt-4 the ability to bind VEGF with an affinity nearly identical to that of wild-type Flt-1. Furthermore, transfected cells expressing these chimeric Flt-4 receptors exhibited increased DNA synthesis in response to VEGF or PlGF. These results demonstrate that a single Ig-like domain is the major determinant for VEGF-PlGF interaction and that binding to this domain may initiate a signal transduction cascade.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890165      PMCID: PMC452229     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  49 in total

Review 1.  Dimerization of cell surface receptors in signal transduction.

Authors:  C H Heldin
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

2.  Beta PDGFR-IgG chimera demonstrates that human beta PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding.

Authors:  M A Heidaran; D Mahadevan; W J Larochelle
Journal:  FASEB J       Date:  1995-01       Impact factor: 5.191

3.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Authors:  L P Aiello; E A Pierce; E D Foley; H Takagi; H Chen; L Riddle; N Ferrara; G L King; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

4.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

6.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.

Authors:  F Shalaby; J Rossant; T P Yamaguchi; M Gertsenstein; X F Wu; M L Breitman; A C Schuh
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

7.  Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.

Authors:  K Pajusola; O Aprelikova; G Pelicci; H Weich; L Claesson-Welsh; K Alitalo
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

8.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.

Authors:  L Seetharam; N Gotoh; Y Maru; G Neufeld; S Yamaguchi; M Shibuya
Journal:  Oncogene       Date:  1995-01-05       Impact factor: 9.867

Review 9.  Endothelial receptor tyrosine kinases involved in angiogenesis.

Authors:  T Mustonen; K Alitalo
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

10.  An immunoglobulin-like domain determines the specificity of neurotrophin receptors.

Authors:  R Urfer; P Tsoulfas; L O'Connell; D L Shelton; L F Parada; L G Presta
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

View more
  28 in total

1.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.

Authors:  Napoleone Ferrara
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

2.  The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling.

Authors:  J P Labrador; R Brambilla; R Klein
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

Review 3.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 4.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

5.  Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies.

Authors:  Yan Gong; Eric Bourhis; Cecilia Chiu; Scott Stawicki; Venita I DeAlmeida; Bob Y Liu; Khanhky Phamluong; Tim C Cao; Richard A D Carano; James A Ernst; Mark Solloway; Bonnee Rubinfeld; Rami N Hannoush; Yan Wu; Paul Polakis; Mike Costa
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 6.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Ten years of anti-vascular endothelial growth factor therapy.

Authors:  Napoleone Ferrara; Anthony P Adamis
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

9.  A fluorescence polarization assay for identifying ligands that bind to vascular endothelial growth factor.

Authors:  Kimberly J Peterson; Jack D Sadowsky; Elizabeth A Scheef; Soumen Pal; Katerina D Kourentzi; Richard C Willson; Emery H Bresnick; Nader Sheibani; Samuel H Gellman
Journal:  Anal Biochem       Date:  2008-03-28       Impact factor: 3.365

10.  Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries.

Authors:  F Belgore; A Blann; D Neil; A S Ahmed; G Y H Lip
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.